Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total-Body [18F]F-AraG PET/CT Imaging in PASC
NCT07076862Phase 1Recruiting
- Sponsor
- University of California, Davis
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluorine f 18 ara-g in post-acute sequelae of SARS-CoV-2 infection (PASC) (4 arms), sponsored by University of California, Davis. Primary endpoints: Quantification of [18F]F-AraG uptake kinetics, Correlation between [18F]F-AraG uptake parameters and blood-based markers of immune dysregulation and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
fluorine f 18 ara-g
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT07076862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076862.